Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

4 clinical studies listed.

Filters:

Complement 3 Glomerulopathy

Tundra lists 4 Complement 3 Glomerulopathy clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT07598448

A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain

This study aims to characterize the patient profiles and the clinical experience of iptacopan treatment in adult patients with C3G treated through an early access program (EAP) in Spain.

Gender: All

Ages: 18 Years - 100 Years

Updated: 2026-11-17

2 states

Complement 3 Glomerulopathy
TERMINATED

NCT05162066

Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)

The objective of this study was to determine the safety and therapeutic potential of BCX9930 in participants with C3G, IgAN, or PMN.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-10

Complement 3 Glomerulopathy
Immunoglobulin A Nephropathy
Membranous Nephropathy
COMPLETED

NCT04572854

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

This is a Phase 2, multicenter, open-label, randomized, controlled study designed to evaluate the safety and efficacy of pegcetacoplan in patients who have post-transplant recurrence of C3G or IC-MPGN.

Gender: All

Ages: 18 Years - Any

Updated: 2026-04-21

10 states

C3G
IC-MPGN
Renal Transplant
+9
ACTIVE NOT RECRUITING

NCT05809531

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

This study is designed as a long-term extension to Study APL2-C3G-310, and is being conducted to establish the long-term safety and efficacy of pegcetacoplan in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN).

Gender: All

Ages: 12 Years - Any

Updated: 2026-04-02

16 states

C3G
IC-MPGN
C3 Glomerulopathy
+9